Press Releases

Showing 36-70 of 261

First Prev 1 2 3 4 5 6 7 8 Next Last

2012
December
December 17	Abbott Announces New Testosterone Test to Measure the Hormone at Low Levels
December 17	AbbVie Inc. Common Stock Approved for Listing on NYSE Euronext Paris
December 14	Abbott Declares 356th Consecutive Quarterly Dividend
December 13	New Study Shows Promising Results For Tests That Can Help Doctors Better Evaluate Potential Heart Attacks
December 7	Abbott Announces Effectiveness of AbbVie Form 10 Registration Statement

November
November 28	Abbott Board of Directors Approves Separation of AbbVie and Declares Special Dividend Distribution of AbbVie Stock
November 27	Abbott’s HUMIRA® (Adalimumab) Approved in Europe for Severe Active Pediatric Crohn’s Disease
November 13	Abbott Announces Phase 3 Hepatitis C Program Details
November 12	Abbott Announces First Long-term Patient-reported Health Outcomes Data for Investigational Use of HUMIRA® (Adalimumab) in Patients with Active Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
November 12	Abbott Announces Results of Analysis Exploring the Use of HUMIRA® (Adalimumab) in Simultaneously Achieving Three Key Treatment Goals for Rheumatoid Arthritis
November 10	Abbott Presents Promising Phase 2b Interferon-free Hepatitis C Results at 2012 Liver Meeting®
November 2	Statement: Abbott and the Abbott Fund Donate $1 Million in Funding and Products to Support Hurricane Sandy Relief Efforts

October
October 30	Abbott Introduces Ensure Complete™ Shakes For Adults
October 24	Abbott Announces Data Evaluating Reduction of Steroid Usage with HUMIRA® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis
October 24	Abbott’s ALK Test is Now Available in Europe as a Companion Diagnostic Test to Aid in Identifying Patients for Targeted Lung Cancer Therapy
October 23	Abbott Announces New Data Evaluating Mucosal Healing with HUMIRA® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis
October 22	Abbott Announces Three-Year Long-Term Data Evaluating Efficacy with HUMIRA® (Adalimumab) For Patients with Moderately to Severely Active Ulcerative Colitis
October 19	Abbott Receives Positive Opinion from CHMP for HUMIRA® Use in Pediatric Crohn's Disease
October 17	Abbott Reports Double Digit Earnings Per Share Growth in the Third Quarter
October 15	Abbott's Investigational Interferon-Free Hepatitis C Treatment Regimen Achieved SVR12 (Observed Data) Rates in 99 Percent of Treatment-Naïve and 93 Percent in Prior Null Responders for Genotype 1 Patients in Phase 2b Study
October 12	Abbott Awards Two Scholarships to Inspirational Students Living with Cystic Fibrosis
October 3	Abbott Hosts Conference Call for Third-Quarter Earnings

September
September 28	Abbott's HUMIRA® (adalimumab) Receives U.S. FDA Approval for the Treatment of Adult Patients with Moderate to Severe Ulcerative Colitis
September 25	Abbott Announces International Launch of the Absorb™ Bioresorbable Vascular Scaffold
September 21	The Journal Science Again Recognizes Abbott as One of the Top Employers in the Biotech and Pharmaceutical Industry
September 18	Abbott Named to Working Mother Magazine's 'Best Companies' List for Twelve Consecutive Years
September 13	Abbott Declares 355th Consecutive Quarterly Dividend
September 13	Abbott Recognized for Leading Citizenship Performance for Eighth Consecutive Year by Dow Jones Sustainability Indexes
September 12	According to New Survey, Most Men are Not Proactive about Their Health Despite the Desire to Live Long Lives
September 6	Abbott to Collaborate with Astellas in CMV Vaccine Trial

August
August 30	Abbott's HUMIRA® (Adalimumab) Approved in Europe for Expanded Treatment of Crohn’s Disease (CD)
August 28	Abbott Announces CE Mark for Highly Sensitive Testosterone Test to Measure the Hormone at Low Levels
August 20	Abbott Announces CE Mark and European Launch of Next-Generation XIENCE Xpedition™ Drug Eluting Stent
August 13	Public Voting Now Open to Help Grant Two $20,000 Abbott CFCareForward Scholarships to Students with Cystic Fibrosis
August 7	Abbott's Omnilink Elite® Vascular Balloon-Expandable Stent System Receives FDA Approval for Treatment of Iliac Artery Disease

First Prev 1 2 3 4 5 6 7 8 Next Last

Narrow by Year

Narrow to Show

For a different perspective on Abbott News. . .

View Abbott Feature Stories

© 2006, 2013 Abbott Laboratories, Abbott Park, Illinois, USA

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott Laboratories, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott Laboratories, except to identify the product or services of the company.